The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Part of paid clinical trials in New York, New York.

Sponsor
Madeline Fields
Study ID
NCT05019885
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Drug Resistant Epilepsy
  • Medically Refractory Epilepsy
  • Refractory Epilepsy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ketamine Hydrochloride — DRUG
    Three times a week (M, W, F) for 2 consecutive weeks.

Study Details

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

Key Dates

Start date
Aug 26, 2022
Status verified
Aug 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: IV Ketamine Hydrochloride
    dose 0.5mg/kg of IV Ketamine Hydrochloride over 40 min

Primary Outcome Measure

Number of participants with seizure reduction [ Time Frame: 2 week during active treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai HospitalNew YorkNew York10035
Onome Eka, MBBS MPH
[email protected]
9179825055
Madeline Fields (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site
Mount Sinai Hospital· New York, NY

Related Studies